Bipolar Disorder Therapeutics Market Size & Share, by Drug Type (Mood Stabilizers, Antipsychotics Drugs, Antidepressant Drugs) and By Mechanism of Action (Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines and Beta-Blockers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Growing Prevalence Of Mental Health Disorders (MHDs) Across The Globe
  According to the Centers for Disease Control and Prevention, most of the MHDs coexist with other diseases such as cardiovascular disease, diabetes, or obesity. In 2017, in the US, depression affected almost 10% of the young population, and 4% of the population lived with serious mental illnesses such as schizophrenia, bipolar disorder, and major depression. An increment of these MHDs is estimated to act as an important role in the bipolar disorder therapeutics market.
• Rising Awareness About The Bipolar Disorder
  A rise in patient awareness, healthcare awareness, and an increase in investment in research and developments, are some factors that are expected to drive the market over the forecast period.

Challenges

• Long Term Side Effects
  Bipolar disorder medication can have long-term side-effects such as tremors, muscle spasms, involuntary movements, dry mouth, sore throat, weight gain, increased glucose and lipid levels in the blood and sedation can impede the growth of the bipolar disorder therapeutics market.